Document Detail

Leflunomide prevents the development of experimentally induced myasthenia gravis.
MedLine Citation:
PMID:  7672879     Owner:  NLM     Status:  MEDLINE    
Myasthenia gravis is an autoimmune disease in which autoantibodies specific to the acetylcholine receptor (AChR) are formed, leading to a gradual destruction of the receptors in muscles that are responsible for picking up nerve impulses, and results in weakness and eventual loss of muscle function. The novel immunomodulating drug leflunomide (HWA 486) has been shown to be very effective in preventing and halting ongoing disease in an array of experimental autoimmune disorders and reactions leading to organ graft rejection. Further, recent data from phase II clinical trials indicate that this drug is efficacious and is safe in humans with rheumatoid arthritis. In the studies reported here, we found that rats immunized with AChR-protein and not receiving leflunomide developed experimental myasthenia gravis (EMG) between day 7 and 11 post-immunization, and about 79% of these animals expressed clinical signs of disease. Treatment of AChR-protein immunized rats with leflunomide, from the day of disease induction, totally suppressed the development of EMG. Thus, the results we have obtained using leflunomide in EMG indicate that this drug could be beneficial in combating myasthenia gravis in humans.
B Vidic-Dankovic; D Kosec; M Damjanovic; S Apostolski; K Isakovic; R R Bartlett
Related Documents :
11778659 - The dual association between lymphoma and autoimmunity.
18606079 - Immunomodulatory approaches to the management of chronic urticaria: an immune-mediated ...
20388059 - Development of small-molecule therapies for autoimmune diseases.
21958629 - A review of the risk of contamination of semen and embryos during cryopreservation and ...
8114519 - Involution of the thymus revisited: immunological trade-offs as an adaptation to aging.
16126509 - A genetic basis for shared autoimmunity in mouse models.
9694539 - Oxidation of low density lipoproteins in the pathogenesis of atherosclerosis.
3806069 - The relationships of anhedonia and the process-reactive dimension to season of birth an...
23283069 - Burden of chronic respiratory diseases (crd) in middle east and north africa (mena).
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  International journal of immunopharmacology     Volume:  17     ISSN:  0192-0561     ISO Abbreviation:  Int. J. Immunopharmacol.     Publication Date:  1995 Apr 
Date Detail:
Created Date:  1995-10-18     Completed Date:  1995-10-18     Revised Date:  2003-11-14    
Medline Journal Info:
Nlm Unique ID:  7904799     Medline TA:  Int J Immunopharmacol     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  273-81     Citation Subset:  IM    
Immunology Research Center, Belgrade, Serbia Montenegro.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Autoantibodies / biosynthesis
Autoimmune Diseases / etiology,  immunology,  prevention & control*
Flow Cytometry
Immunosuppressive Agents / pharmacology,  therapeutic use*
Isoxazoles / pharmacology,  therapeutic use*
Myasthenia Gravis / etiology,  immunology,  prevention & control*
Rats, Inbred Strains
Receptors, Cholinergic / immunology
T-Lymphocyte Subsets / drug effects,  immunology
Thymus Gland / drug effects,  pathology
Time Factors
Reg. No./Substance:
0/Autoantibodies; 0/Immunosuppressive Agents; 0/Isoxazoles; 0/Receptors, Cholinergic; 75706-12-6/leflunomide

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Immunosuppressive activities of 6(5H)-phenanthridinone, a new poly(ADP-ribose)polymerase inhibitor.
Next Document:  Immunoregulatory potential of exogenous Schistosoma mansoni soluble egg antigen in a model of experi...